Ibogaine Legality by Country

Iboga is a traditional plant medicine with no scheduling restrictions.

Ibogaine is not specifically prohibited in Colombia. The Constitutional Court has established that personal possession of drugs for personal use is protected. Colombia has a strong plant medicine tradition. No major ibogaine treatment centers operate publicly, but the legal environment is permissive.

Iboga is native to Gabon and deeply embedded in Bwiti culture. Completely legal.

Ibogaine is legal in Jamaica. The country has become a popular destination for plant medicine retreats.

Ibogaine is unscheduled in Mexico -- not listed as a controlled substance under Mexican federal law. Medical clinics operate legally, primarily in Tijuana and Cancun. Mexico is the world primary destination for ibogaine treatment, especially for US patients. The Stanford veterans study (Polanco et al., 2023) was conducted at a Mexican clinic. Quality varies significantly between facilities.

Ibogaine is not scheduled under Dutch law (Opiumwet). Retreat centers and clinics operate legally. The Netherlands has a long tradition of harm-reduction drug policy and is the primary European destination for ibogaine treatment.

Ibogaine is not controlled in Panama. Treatment centers operate legally.

Ibogaine is not controlled in Peru, which has a long tradition of plant medicine use.

Czech Republic decriminalized possession of small amounts of most substances. Ibogaine is not specifically scheduled but falls under general rules. Personal possession of small amounts (typically up to 0.3g) is a civil infraction. Czech Republic has a pragmatic drug policy similar to Portugal but less formally structured.

Portugal decriminalized personal possession of all drugs in 2001 (Law 30/2000). Possession of up to a 10-day personal supply results in referral to a Dissuasion Commission, not criminal prosecution. Sale and trafficking remain criminal. No open ibogaine clinics in Portugal; patients use retreats in Netherlands or Spain.

Ibogaine is not specifically scheduled in Spain but falls under general controlled substances law. Personal possession for private use is an administrative offense (fine), not criminal -- similar to Portugal. Sale and trafficking remain criminal. Patients most often travel to Mexico, Netherlands, or Costa Rica for treatment.

Switzerland uses a four-pillar drug policy (prevention, treatment, harm reduction, repression). Ibogaine is not specifically listed in Swiss narcotics schedules, creating a legal gray area. Small amounts for personal use are treated civilly. Some Swiss clinics have operated.

Ibogaine is listed on Health Canada’s Prescription Drug List but is not a CDSA controlled substance and has no authorized product. Clinical research requires Health Canada authorization. Most Canadian patients travel to Mexico.

Israel has an active ibogaine research program supported by the Ministry of Health and IDF (Israel Defense Forces), primarily targeting veterans with PTSD. Ibogaine remains controlled outside research contexts. Israel is a leader in psychedelic-assisted therapy research.

Ibogaine is classified as a controlled substance under Group II of Slovenia's prohibited drugs schedule, where it has been explicitly listed since 2023. Under amendments effective October 17, 2026, the production, distribution, and medical use of ibogaine are permitted exclusively within approved clinical trials conducted in accordance with Slovenia's Medicinal Products Act. Ibogaine treatment outside authorized clinical research is not legally permitted.

Ibogaine is a Schedule I controlled substance under federal law (DEA). In 2025, Texas allocated $50 million for ibogaine clinical research to develop FDA-approved treatments for opioid use disorder. Colorado SB 23-290 (2023) similarly funded research. In April 2026, a US Executive Order directed federal agencies to accelerate review of ibogaine for veterans with PTSD and TBI. The FDA has not approved ibogaine. This is the most active legislative period for ibogaine in US history.

Ibogaine is listed in Schedule 4 (Prescription Only Medicine) under Australia's Poisons Standard, not Schedule 9 (the category for substances like heroin with no accepted medical use). No ibogaine product is on the Australian Register of Therapeutic Goods, so it has not been assessed for safety or efficacy, and access/supply/importation are subject to additional federal and state/territory requirements.

Ibogaine is not scheduled as a controlled narcotic in Brazil, but ANVISA (the national health regulator) has stated in official notices that ibogaine treatments are not regulated and that commercial sale of ibogaine is illegal, since no ibogaine product has been evaluated or authorized for marketing. The absence of narcotics scheduling does not mean clinics are authorized to sell or administer it as a treatment.

Ibogaine is not a scheduled narcotic in Costa Rica, but it is not approved for medical/therapeutic use either. On January 27, 2025, the Ministry of Health issued a formal warning that ibogaine and ayahuasca products lack sanitary registration and that facilities offering them for healing must hold a valid health establishment permit. Separately, the government agency IAFA must approve any addiction treatment program under Law No. 8289. We are not aware of any Costa Rica ibogaine retreat holding that approval.

Ibogaine and noribogaine have been classified as prescription-only medicines in New Zealand since 2010. Ibogaine remains an unapproved medicine, but Section 25 of the Medicines Act allows an authorized medical practitioner to prescribe an unapproved medicine for an individual patient under their care. This is a real but narrow physician-mediated pathway, not routine open access; a 2015 Health and Disability Commissioner case involving a New Zealand ibogaine provider found specific breaches of care standards.

Ibogaine is listed in Schedule 6 of South Africa's medicines scheduling framework under the Medicines and Related Substances Control Act. It is not an unscheduled substance that clinics can freely supply: Schedule 6 substances cannot be advertised directly to the public or dispensed on repeat prescription, and prescribing requires a licensed medical professional.

Ibogaine is not specifically scheduled in Argentina but falls under general controlled substance regulations.

Ibogaine is controlled under Austrian narcotics law.

Ibogaine is illegal in Belgium.

Ibogaine is a controlled substance in China.

Ibogaine is a controlled substance in Denmark.

Ibogaine is classified as a dangerous substance in France. Possession and use are illegal.

Ibogaine is controlled under BtMG (Betaeubungsmittelgesetz). Possession without prescription is illegal. Germany legalized cannabis in April 2024 but this did not affect ibogaine. German patients typically travel to the Netherlands or Mexico.

Ibogaine falls under the NDPS Act and is illegal in India.

Ibogaine is a Schedule 1 controlled substance in Ireland.

Ibogaine is controlled under Italian law. Possession and trafficking are illegal.

Ibogaine is strictly controlled in Japan under the Narcotics and Psychotropics Control Act.

Ibogaine is a Schedule II narcotic in Norway.

Ibogaine is a controlled substance in Poland.

Ibogaine is illegal in Russia.

Ibogaine is explicitly listed as a controlled psychoactive substance under Serbia's Regulation on the List of Psychoactive Controlled Substances (Official Gazette No. 12/2026). Both ibogaine (CAS 83-74-9) and the Tabernanthe iboga plant are included in List 4.

Singapore has some of the strictest drug laws in the world. Ibogaine possession carries severe penalties.

Ibogaine is illegal in Sweden under the Narcotics Act.

Ibogaine is a Category 1 narcotic in Thailand with severe penalties.

Ibogaine is a controlled substance in Ukraine.

Ibogaine is not identified by name as a controlled drug under the Misuse of Drugs Act 1971. The Psychoactive Substances Act 2016 makes it an offence to produce, supply, import or export any psychoactive substance, with a maximum penalty of seven years' imprisonment; it does not generally criminalize simple possession outside custodial settings. No NHS pathway or licensed private clinic offers ibogaine treatment in the UK.

Ibogaine was not found by name in the controlled-substance list examined. However, broader provisions covering groups of substances require clarification. The legality of import, supply, and treatment remains unconfirmed.

Ibogaine was not found by name in the Greek Ministry of Health’s controlled-substance tables updated in October 2026. This does not establish that its import, sale, or use in treatment is lawful.

Ibogaine is not explicitly listed in the reviewed Bahamian controlled-substance schedules, and ibogaine treatment centers operate in the country. However, the legal status of ibogaine remains uncertain, particularly regarding its importation, commercial supply, and administration in medical settings. The presence of treatment providers does not establish that their activities are officially authorized or medically regulated. Independent confirmation from the relevant Bahamian authorities is recommended.